A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

ABSTRACT:

Background

Brain metastases are a common complication of advanced non-small cell lung cancer (NSCLC). Patients with brain metastases were excluded from the registration trials of bevacizumab that showed a survival benefit with the use of angiogenesis inhibition.

Methods

In this study, we pooled data from two separate trials designed to evaluate the risk of central nervous system (CNS) hemorrhage in patients with stable treated brain metastases to look specifically at both the safety and efficacy of bevacizumab and pemetrexed when used as second-line treatment in NSCLC patients with stable treated brain metastases.

Results

We report acceptable safety and promising efficacy from our analysis.

Conclusions

Our study adds further evidence of safety of administering

SUBMITTER: Gubens MA 

PROVIDER: S-EPMC5863135 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature